Peyronie's disease: What's around the bend?

Bilgutay, Aylin N.; Pastuszak, Alexander W.

doi:10.4103/0970-1591.173107

Cited by 12 publications

(3 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 8 9 ] Thereafter, IFN-α2b was introduced as therapy for many fibrotic conditions such as PD, keloid scars, and scleroderma. [ 10 ]…”

Section: Discussionmentioning

confidence: 99%

“…Oral therapy includes vitamin E, tamoxifen, colchicine, potaba (potassium aminobenzoate), coenzyme Q10, omega-3 fatty acid, and many more. [ 10 11 ] Many nonpharmacological, nonsurgical measures as extracorporeal shock wave, hyperthermia therapy, penile traction therapy, and radiotherapy had been attempted. Intralesional delivery of hypo-proliferating agents, including collagenase, verapamil, steroids, interferon (IFN)-α2b, orgotein, onabotulinumtoxinaA, and many under evaluation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prospective study to evaluate the clinical outcome of intralesional interferon-α2b in the management of Peyronie's disease

et al. 2018

View full text Add to dashboard Cite

Context:Interferon (IFN)-α2b in Peyronie's disease (PD).Aims:This study aims to evaluate clinical efficacy of the IFN-α2b in both subjective and objective manner for the treatment of PD and compared with previously used intralesional verapamil in terms of cost-benefit analysis.Settings and Design:Prospective study.Materials and Methods:A prospective study conducted from January 2013 to July 2016 in the Department of Urology, Government Medical College, Kota, Rajasthan, India. We included patients with identifiable Peyronie's plaque with or without pain, curvature ranging between 30 and 90 degrees. We excluded patients with a calcified plaque and the ventral location of the plaque, any infective foci over the penis, erectile dysfunction due to other etiologies and patients who had received previous intralesional therapy. Patients were evaluated by clinical history, physical examination including plaque location, size, consistency, and penile curvature. Patients received intralesional IFN-α2b in a dose of 3 × 106 IU. Patients completed the visual analogue pain (VAS) score for pain, and International Index of Erectile Function-5 (IIEF-5) questionnaire at first visit as well as at follow-up of 1 month and 3 months.Statistical Analysis Used:Comparisons were performed using the paired Student's t-test and Chi-square tests as appropriate. Patient's objective and subjective clinical characteristics were described as a means (standard deviation).Results:We included 86 patients in this study. Patients had a mean age of 48.6 years, mean plaque volume 256 mm3, and disease duration of 15.2 years. After 1 month of treatment, there was a significant change in plaque volume 256–60.8 mm3; P < 0.01) and penile curvature 34.8–24.6°; P < 0.01). The patients reported significant improvement in pain score VAS and IIEF-5.Conclusions:IFN-α2b, as minimal invasive (intralesional) options for the treatment of PD, demonstrated significant improvement in plaque volume, penile curvature with minimal complications. Patients subjectively reported significant improvement in pain on erection and sexual activities. IFN-α2b and verapamil had an almost similar clinical outcome, but verapamil at much lower cost.

show abstract

“…[ 8 9 ] Thereafter, IFN-α2b was introduced as therapy for many fibrotic conditions such as PD, keloid scars, and scleroderma. [ 10 ]…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prospective study to evaluate the clinical outcome of intralesional interferon-α2b in the management of Peyronie's disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…This indicates that other factors, e.g., genetics, may also contribute to the development of PD. Some potent risk factors for PD are a history of nongonococcal urethritis, smoking, inflammatory genital disease in a partner, fibromatous lesions of the genital track, and history of genital tract surgery ( 14 ).…”

Section: Epidemiology and Etiologymentioning

confidence: 99%

Peyronie’s disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up

Althakafi

Alhathal

2016

Transl. Androl. Urol.

View full text Add to dashboard Cite

Peyronie’s disease (PD), a fibromatous disorder of the tunica albuginea of the penile corpus cavernosum, named after the French physician Francois de la Peyronie, is characterized by pain, plaque formation, penile curvature, and plaque calcification. The epidemiological data on PD is inconsistent, with recent reports stating a prevalence of up to 9%, and the condition affecting men of all ages, from teenagers to septuagenarians. We are just beginning to elucidate the role of genetics as a causative factor for PD. Chromosomal abnormalities and single-nucleotide polymorphisms have been shown to be associated with fibrotic diatheses. Tunical mechanical stress and microvascular trauma are major contributory factors to the pathophysiology of PD. The diagnosis of PD can be made using a combination of clinical history, physical examination and, sometimes, imaging modalities. A better understanding of the molecular pathophysiology of this condition remains paramount for the development of newer and more effective disease-targeted interventions.

show abstract